Rising Incidence of Psychiatric and Neurodegenerative Disorders Drive the Global CNS Therapeutics Market

The global market for CNS Therapeutics is projected to reach US$145 billion by 2024, driven by increasing incidence of CNS disorders, rising acceptance of new therapies and new classes of drugs, aging population and a parallel rise in Parkinson's and Alzheimer's disease.

The global CNS therapeutics market is on a growth trajectory, and the various factors driving market growth include increasing incidence of CNS diseases, rapidly growing aging population, and rising healthcare expenditure. Unmet healthcare needs for detecting and treating CNS conditions brings to fore the untapped potential in the market. Companies are therefore investing to develop novel drugs in the neurodegenerative segment. The industry has crossed some milestones in recent years with regard to developing therapies with relatively lesser side effects, convenient drug administration, and efficient performance. Greater patient compliance as a result of increased awareness about the benefits of the drugs, such as improved quality of life and reduction/prevention of disease co-morbidity, will also help spur patient adherence to prescribed treatment regimes. Acceptance of new therapies and new classes of drugs will additionally benefit the market.

CNS drugs, specifically for neurodegenerative diseases, are set to become the next big healthcare movement over the coming decades, with Alzheimer's and Parkinson's diseases as the two most important therapeutic categories. Introduction of new class of Alzheimer's drugs, including anti-amyloid proteins, anti-tau proteins, cholinergic and nicotine receptor agonists, Neuro protective drugs, and GABA receptor modulators, will also help support growth in this space. The market is also witnessing the launch of novel therapies for the treatment of Parkinson's disease, such as adenosine and andrenergic agonists, glutamate receptor modulators, and dopamine receptor agonists. Other disease conditions propelling increases in CNS prescriptions, although to a lesser extent, include pain manifestations, psychiatric disorders (schizophrenia, sleep disorders, depression and anxiety), cerebrovascular disorders, stroke, seizures, cognitive and memory disorders, and ailments caused due to injuries and physical trauma.

The U.S. represents the largest market worldwide, closely followed by Europe. The U.S. market is driven by well-established healthcare infrastructure, increased patient population, and the widespread use of drugs. Significant research and development activities, and the presence of several major pharmaceutical companies in the regions also support market growth. Asia-Pacific represents the fastest growing market with a value CAGR of 3.6% over the analysis period. While factors such as increasing population and rising prevalence of CNS disorders, especially among the 65+ age group, would act as general growth drivers, other factors such as increased focus of governments on improving their healthcare systems would aid market growth in the ensuing years.

Key players in the market include AbbVie Inc., Alkermes Plc., Allergan Plc., AstraZeneca Plc., BIAL Group, Bristol-Myers Squibb, Eisai Co., Ltd., Endo Pharmaceuticals Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Purdue Pharma L.P., Sanofi, Shire Plc, Sumitomo Dainippon Pharma Co., Ltd. Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group, among others.

View infographic | Report TOC